12710 Federal Register / Vol. 87, No. 44 / Monday, March 7, 2022 / Notices 

Purpose: The establishment and 

formation of the HEW is to provide 

input to the ACD, CDC on agency-wide 

activities related to the scope and 

implementation of CDC’s CORE (an 

acronym for C-cultivate comprehensive 

health equity science, O-optimize 

interventions, R-reinforce and expand 

robust partnerships, and E-enhance 

capacity and workforce diversity and 

inclusion) strategy around health equity. 

The HEW membership will be 

comprised of approximately 15 

members. It will be chaired by two 

current ACD, CDC Special Government 

Employees. HEW co-chairs will present 

their findings, observations, and work 

products at one or more ACD, CDC 

meetings for discussion, deliberation, 

and decisions (final recommendations 

to CDC). 

Nomination Criteria: HEW members 

will serve terms ranging from six 

months to one year and be required to 

attend HEW meetings approximately 1– 

2 times per month (virtually or inperson), and contribute time in between 

meetings for research, consultation, 

discussion, and writing assignments. 

Nominations are being sought for 

individuals who have the expertise and 

qualifications necessary to contribute to 

the accomplishments of the 

committee’s/workgroup’s objectives. 

Nominees will be selected based on 

expertise in the fields of health equity; 

public health science and practice; 

public health policy development, 

analysis, and implementation. To 

ensure a diverse workgroup 

composition, nominees with front line 

and field experience at the local, state, 

tribal and territorial levels are 

encouraged to apply. This includes 

nominees with experience working for, 

and with, community-based 

organizations and other non-profit 

organizations. Federal employees will 

not be considered for membership. 

Selection of members is based on 

candidates’ qualifications to contribute 

to the accomplishment of the HEW’s 

objectives. 

HHS policy stipulates that 

membership be balanced in terms of 

points of view represented and the 

workgroup’s function. Appointments 

shall be made without discrimination 

based on age, race, ethnicity, gender, 

sexual orientation, gender identity, HIV 

status, disability, and cultural, religious, 

or socioeconomic status. Nominees 

must be U.S. citizens and cannot be fulltime employees of the U.S. Government. 

Current participation on federal 

workgroups or prior experience serving 

on a federal advisory committee does 

not disqualify a candidate; however, 

HHS policy is to avoid excessive 

individual service on advisory 

committees and multiple committee 

memberships. Interested candidates 

should submit the following items: 

D A one-half to one-page cover letter 

that includes your understanding of, 

and commitment to, the time and work 

necessary; one to two sentences on your 

background and experience; and one to 

two sentences on the skills/perspective 

you would bring to the HEW. 

D Current curriculum vitae which 

highlights the experience and work 

history being sought relevant to the 

criteria set forth above, including 

complete contact information 

(telephone numbers, mailing address, 

email address). 

Nominations may be submitted by the 

candidate him or herself, or by the 

person/organization recommending the 

candidate. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–04690 Filed 3–4–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP)—CE22–003, 

Rigorously Evaluating Programs and 

Policies To Prevent Child Sexual 

Abuse (CSA); Amended Notice of 

Meeting 

Notice is hereby given of a change in 

the meeting of the Disease, Disability, 

and Injury Prevention and Control 

Special Emphasis Panel (SEP)—CE22– 

003, Rigorously Evaluating Programs 

and Policies to Prevent Child Sexual 

Abuse (CSA), April 19–20, 2022, 8:30 

a.m., EDT–5:30 p.m., EDT, Web 

Conference, in the original FRN. The 

meeting was published in the Federal 

Register on January 14, 2022, Volume 

87, Number 10, page 2439. 

The meeting is being amended to 

change the meeting date and should 

read as follows: 

CE22–003, Rigorously Evaluating 

Programs and Policies to Prevent Child 

Sexual Abuse (CSA): April 19, 2022. 

The meeting is closed to the public. 

FOR FURTHER INFORMATION CONTACT: 

Aisha L. Wilkes, M.P.H., Scientific 

Review Officer, National Center for 

Injury Prevention and Control, CDC, 

4770 Buford Highway NE, Mailstop 

S106–9, Atlanta, Georgia 30341, 

Telephone (404) 639–6473, AWilkes@

cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–04681 Filed 3–4–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Disease, Disability, and Injury 

Prevention and Control Special 

Emphasis Panel (SEP)—RFA–CE22– 

002, Grants To Support New 

Investigators in Conducting Research 

Related To Preventing Interpersonal 

Violence Impacting Children and 

Youth; Amended Notice of Meeting 

Notice is hereby given of a change in 

the meeting of the Disease, Disability, 

and Injury Prevention and Control 

Special Emphasis Panel (SEP)—RFA– 

CE22–002, Grants to Support New 

Investigators in Conducting Research 

Related to Preventing Interpersonal 

Violence Impacting Children and Youth, 

March 8–9, 2022, 8:30 a.m., EDT–5:30 

p.m., EDT, Web Conference, in the 

original FRN. The meeting was 

published in the Federal Register on 

January 5, 2022, Volume 87, Number 3, 

page 460. 

The meeting is being amended to 

change the meeting date and should 

read as follows: 

RFA–CE22–002, Grants to Support 

New Investigators in Conducting 

Research Related to Preventing 


khammond on DSKJM1Z7X2PROD with NOTICES
Federal Register / Vol. 87, No. 44 / Monday, March 7, 2022 / Notices 12711 

Interpersonal Violence Impacting 

Children and Youth: March 8, 2022. 

The meeting is closed to the public. 

FOR FURTHER INFORMATION CONTACT: 

Aisha L. Wilkes, M.P.H., Scientific 

Review Officer, National Center for 

Injury Prevention and Control, CDC, 

4770 Buford Highway NE, Mailstop 

S106–9, Atlanta, Georgia 30341, 

Telephone (404) 639–6473, AWilkes@

cdc.gov. 

The Director, Strategic Business 

Initiatives Unit, Office of the Chief 

Operating Officer, Centers for Disease 

Control and Prevention, has been 

delegated the authority to sign Federal 

Register notices pertaining to 

announcements of meetings and other 

committee management activities, for 

both the Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Kalwant Smagh, 

Director, Strategic Business Initiatives Unit, 

Office of the Chief Operating Officer, Centers 

for Disease Control and Prevention. 

[FR Doc. 2022–04680 Filed 3–4–22; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Medicare & Medicaid 

Services 

[CMS–3425–N] 

Announcement of the Approval of 

COLA as an Accreditation 

Organization for the Specialty of 

Pathology To Include Histopathology, 

Cytology and Oral Pathology Under the 

Clinical Laboratory Improvement 

Amendments of 1988 

AGENCY: Centers for Medicare & 

Medicaid Services (CMS), HHS. 

ACTION: Notice. 

SUMMARY: This notice announces the 

application of COLA for approval as an 

accreditation organization for clinical 

laboratories under the Clinical 

Laboratory Improvement Amendments 

of 1988 (CLIA) program for the specialty 

of Pathology to include Histopathology, 

Cytology and Oral Pathology. We have 

determined that COLA meets or exceeds 

the applicable CLIA requirements. In 

this notice, we announce the approval 

and grant COLA deeming authority for 

the specialty of Pathology to include 

Histopathology, Cytology and Oral 

Pathology for a period of 2 years. 

DATES: This notice is effective from 

March 7, 2022 to March 7, 2024. 

FOR FURTHER INFORMATION CONTACT: 

Raelene Perfetto (410) 786–6876. 

SUPPLEMENTARY INFORMATION: 

I. Background and Legislative 

Authority 

On October 31, 1988, the Congress 

enacted the Clinical Laboratory 

Improvement Amendments of 1988 

(CLIA) (Pub. L. 100–578). CLIA 

amended section 353 of the Public 

Health Service Act. We issued a final 

rule implementing the accreditation 

provisions of CLIA on July 31, 1992 (57 

FR 33992). Under those provisions, 

CMS may grant deeming authority to an 

accreditation organization if its 

requirements for laboratories accredited 

under its program are equal to or more 

stringent than the applicable CLIA 

program requirements in 42 CFR part 

493 (Laboratory Requirements). Subpart 

E of part 493 (Accreditation by a Private, 

Nonprofit Accreditation Organization or 

Exemption Under an Approved State 

Laboratory Program) specifies the 

requirements an accreditation 

organization must meet to be approved 

by CMS as an accreditation organization 

under CLIA. 

II. Notice of Approval of COLA for the 

Specialty of Pathology To Include 

Histopathology, Cytology and Oral 

Pathology as an Accreditation 

Organization 

In this notice, we approve COLA as an 

organization that may accredit 

laboratories for purposes of establishing 

their compliance with CLIA 

requirements for the specialty of 

Pathology to include Histopathology, 

Cytology and Oral Pathology. We have 

examined the initial COLA application 

and all subsequent submissions to 

determine its accreditation program’s 

equivalency with the requirements for 

approval of an accreditation 

organization under subpart E of part 

493. We have determined that COLA 

meets or exceeds the applicable CLIA 

requirements. We have also determined 

that COLA will ensure that its 

accredited laboratories will meet or 

exceed the applicable requirements in 

subparts H, I, J, K, M, Q, and the 

applicable sections of R. Therefore, we 

grant COLA approval as an accreditation 

organization under subpart E of part 

493, for the period stated in the DATES

section of this notice for the specialty of 

Pathology and the subspecialties of 

Histopathology, Cytology and Oral 

Pathology. As a result of this 

determination, any laboratory that is 

accredited by COLA during the time 

period stated in the DATES section of this 

notice will be deemed to meet the CLIA 

requirements for the specialty of 

Pathology to include Histopathology, 

Cytology and Oral Pathology, and 

therefore, will generally not be subject 

to routine inspections by a State survey 

agency to determine its compliance with 

CLIA requirements. The accredited 

laboratory, however, is subject to 

validation and complaint investigation 

surveys performed by CMS, or its 

agent(s). 

III. Evaluation of COLA’s Request for 

Approval as an Accreditation 

Organization Under CLIA for the 

Specialty of Pathology To Include 

Histopathology, Cytology and Oral 

Pathology 

The following describes the process 

used to determine that COLA 

accreditation program meets the 

necessary requirements to be approved 

by CMS and that, as such, CMS may 

approve COLA as an accreditation 

program with deeming authority under 

the CLIA program. In reviewing these 

materials, we reached the following 

determinations for each applicable part 

of the CLIA regulations: 

A. Subpart E—Accreditation by a 

Private, Nonprofit Accreditation 

Organization or Exemption Under an 

Approved State Laboratory Program 

COLA submitted its mechanism for 

monitoring compliance with all 

requirements equivalent to conditionlevel requirements, a list of all its 

current laboratories and the expiration 

date of their accreditation, and a 

detailed comparison of the individual 

accreditation requirements with the 

comparable condition-level 

requirements. We have determined that 

COLA policies and procedures for 

oversight of laboratories performing 

laboratory testing for the specialty of 

Pathology to include Histopathology, 

Cytology and Oral Pathology are 

equivalent to those required under the 

CLIA regulations in the matters of 

inspection, monitoring proficiency 

testing (PT) performance, investigating 

complaints, and making PT information 

available. COLA submitted 

documentation regarding its 

requirements for monitoring and 

inspecting laboratories and describing 

its standards regarding data 

management, the inspection process, 

procedures for removal or withdrawal of 

accreditation, notification requirements 

for laboratories out of compliance, and 

accreditation organization resources. We 

have determined that COLA’s 

requirements for monitoring and 

inspecting laboratories are equivalent to 

those required under our regulations for 

laboratories in the areas of data 

management, the inspection process, 

procedures for removal or withdrawal of 

accreditation, notification requirements 


khammond on DSKJM1Z7X2PROD with NOTICES